Zentiva Group, a.s. is a pharmaceutical company headquartered in Prague, Czech Republic. With roots tracing back over 530 years to a historic pharmacy in Prague, it has evolved into a leading European producer of generic and over-the-counter (OTC) medicines.
The company develops, manufactures, and markets a broad portfolio of more than 2,650 products across key therapeutic areas, including cardiology, diabetes, oncology, respiratory diseases, central nervous system disorders, and consumer health. Zentiva operates manufacturing sites in Prague (Czech Republic), Bucharest (Romania), and Ankleshwar (India), ensuring supply to over 100 million patients in more than 40 countries, primarily in Europe.
Employing over 5,000 people, Zentiva focuses on delivering high-quality, affordable medicines. It was previously a subsidiary of Sanofi before being acquired by private equity firm Advent International in 2018.
Also known as Zentiva Group.
12 medicines received positive CHMP opinions, including haemophilia, cancer and rabies treatments; biosimilars and generics endorsed; several applications withdrawn; re-examinations and one refusal confirmed.
